Thyroid Cancer Imaging Using Galectin-3
Author Information
Author(s): Bartolazzi Armando, D'Alessandria Calogero, Parisella Maria Gemma, Signore Alberto, Del Prete Fabrizio, Lavra Luca, Braesch-Andersen Sten, Massari Roberto, Trotta Carlo, Soluri Alessandro, Sciacchitano Salvatore, Scopinaro Francesco
Primary Institution: Cancer Center Karolinska, Karolinska Hospital, Stockholm, Sweden
Hypothesis
Can galectin-3 be used for in vivo imaging of thyroid cancer?
Conclusion
The study demonstrates that galectin-3 can effectively distinguish between benign and malignant thyroid nodules through in vivo imaging.
Supporting Evidence
- Galectin-3 is expressed in over 94% of well-differentiated thyroid carcinomas.
- The imaging technique allowed for clear visualization of galectin-3 expressing tumors.
- Galectin-3 negative tumors were not detected, confirming the specificity of the method.
Takeaway
This study shows that a special molecule called galectin-3 can help doctors see if thyroid lumps are cancerous or not, making it easier to decide who needs surgery.
Methodology
The study used a specific radiotracer to visualize galectin-3 positive thyroid cancer xenografts in mice.
Limitations
The study's findings may not directly translate to human patients without further validation.
Participant Demographics
38 mice were used in the experiments.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website